Generate a tailored SOP for Dr. Marco Ruella. Improve your application with a focused, well-structured draft.
Marco Ruella, MD, is an Associate Professor in the Department of Medicine at the University of Pennsylvania’s Perelman School of Medicine. He specializes in hematological cancers, focusing on lymphoma and leukemia treatments through innovative immunotherapy approaches. Dr. Ruella completed his medical degree at the University of Torino, Italy. He has been instrumental in the development of chimeric antigen receptor (CAR) T-cell therapies, working on solutions to overcome relapse in patients with refractory leukemia and lymphoma. His earlier roles include serving as an attending physician in the Hematology Cell Therapy Division at Mauriziano Hospital and a post-doctoral fellow at the University of Pennsylvania. Over his career, he has received various prestigious awards, including the SITC EMD Serono Cancer Immunotherapy Clinical Fellowship and the NIH K99/R00 Pathway Independence Award. He is a Senior Editor for the journal Molecular Cancer Therapeutics and has played a significant role in shaping cellular therapy committees within the SITC and ASH organizations. Additionally, Dr. Ruella is the founder of viTToria Biotherapeutics, focusing on developing advanced CAR T-cell therapies for cancer and autoimmune diseases.
University of Pennsylvania • Philadelphia, PA
Associate Professor in Medicine specializing in hematologic cancers and immunotherapy.
University of Pennsylvania • Philadelphia, PA
Worked in the Center for Cellular Immunotherapies.
Mauriziano Hospital • Torino, Italy
Physician in the Hematology Cell Therapy Division.
Wharton Doctoral programs cover fields like Finance, Marketing, Management, and Operations, Information and Decisions.